Linked Life Data

8910274

Source:http://linkedlifedata.com/resource/pubmed/id/8910274

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5291
pubmed:dateCreated
1996-12-13
pubmed:abstractText
Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express Fas (also called Apo-1 or CD95) ligand (FasL). In metastatic lesions, Fas-expressing T cell infiltrates were proximal to FasL+ tumor cells. In vitro, apoptosis of Fas-sensitive target cells occurred upon incubation with melanoma tumor cells; and in vivo, injection of FasL+ mouse melanoma cells in mice led to rapid tumor formation. In contrast, tumorigenesis was delayed in Fas-deficient lpr mutant mice in which immune effector cells cannot be killed by FasL. Thus, FasL may contribute to the immune privilege of tumors.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0036-8075
pubmed:author
pubmed:issnType
Print
pubmed:day
22
pubmed:volume
274
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1363-6
pubmed:dateRevised
2007-3-19
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
pubmed:affiliation
Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland. jurg.tschopp@ib.unil.ch
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't